Huarui (300626.SZ) traded flat 0 % during a 24 hours period ending at 05:54 PM Central Europe on Tuesday 27th. One Huarui stock can currently be bought for about CNY 24.23 on popular exchanges. Current supply of Huarui stocks is 180 mn. Huarui has a current market capitalization of CNY 4.5 bn and approximately CNY 106.9 mn worth of Huarui was traded on exchanges in the last 24 hours. Since last month end, Huarui has traded -12.17 % down. Simple moving average of last 200 days is at CNY 30.63. The highest price of past 52 weeks was recorded at CNY 46.8 on 05/26/2026. 52 weeks low was at CNY 11.69 on 12/17/2025.
Here is how related stocks have performed in the past 24 hours:
Focused Photonics Hangzhou (300203.SZ) traded flat 0 % and now trades at CNY 12.12. Focused Photonics Hangzhou has a market capitalisation of CNY 5.4 bn.
Shanghai Ruking Technologi (301525.SZ) traded flat 0 % and now trades at CNY 39.61. Shanghai Ruking Technologi has a market capitalisation of CNY 5.4 bn. Current price/earnings ratio for Shanghai Ruking Technologi is 111.8.
Zhejiang Jingxing Paper (002067.SZ) traded flat 0 % and now trades at CNY 3.6. Zhejiang Jingxing Paper has a market capitalisation of CNY 5.4 bn. Current price/earnings ratio for Zhejiang Jingxing Paper is 37.55.
Jiangyin Electrical Alloy (300697.SZ) traded flat 0 % and now trades at CNY 12.18. Current market capitalisation for Jiangyin Electrical Alloy is CNY 5.4 bn. Current price/earnings ratio for Jiangyin Electrical Alloy is 26.12.
Carsgen Therapeutics (2171.HK) traded down -0.36 % and now trades at HKD 11.25. Current market capitalisation for Carsgen Therapeutics is HKD 6.4 bn. CARsgen Therapeutics Holdings Limited reported preliminary positive outcomes from its investigator‑initiated trial of satri‑cel, a Claudin‑18.2‑targeted CAR‑T therapy, presented at the ESMO Congress. The study involved patients who had undergone radical gastrectomy for high‑risk gastric or gastroesophageal junction cancer. Across a small cohort, the therapy showed a favorable safety profile, with manageable cytokine release syndrome and no neurotoxicity. Early efficacy signals were encouraging: no postoperative recurrence was observed, and the 12‑month disease‑free survival reached a full rate, with one patient’s minimal residual disease converting from positive to negative. CARsgen highlighted these findings as supportive of expanding satri‑cel into earlier‑line and peri‑operative settings, building on its recent approval for later‑line advanced gastric cancer.